Theriva Biologics Inc (TOVX)
1.43
-0.43
(-23.12%)
USD |
NYAM |
Nov 12, 16:00
1.46
+0.03
(+2.10%)
After-Hours: 20:00
Theriva Biologics Research and Development Expense (Quarterly): 2.953M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 2.953M |
| March 31, 2024 | 3.459M |
| December 31, 2023 | 4.196M |
| September 30, 2023 | 4.006M |
| June 30, 2023 | 3.133M |
| March 31, 2023 | 2.977M |
| December 31, 2022 | 3.071M |
| September 30, 2022 | 2.57M |
| June 30, 2022 | 3.485M |
| March 31, 2022 | 2.597M |
| December 31, 2021 | 2.779M |
| September 30, 2021 | 1.972M |
| June 30, 2021 | 1.932M |
| March 31, 2021 | 1.118M |
| December 31, 2020 | 0.979M |
| September 30, 2020 | 0.914M |
| June 30, 2020 | 1.603M |
| March 31, 2020 | 1.635M |
| December 31, 2019 | 1.927M |
| September 30, 2019 | 4.144M |
| June 30, 2019 | 2.594M |
| March 31, 2019 | 2.418M |
| December 31, 2018 | 2.056M |
| September 30, 2018 | 2.846M |
| June 30, 2018 | 3.572M |
| Date | Value |
|---|---|
| March 31, 2018 | 3.37M |
| December 31, 2017 | 3.756M |
| September 30, 2017 | 4.137M |
| June 30, 2017 | 4.831M |
| March 31, 2017 | 6.059M |
| December 31, 2016 | 6.729M |
| September 30, 2016 | 7.061M |
| June 30, 2016 | 7.164M |
| March 31, 2016 | 8.155M |
| December 31, 2015 | 8.858M |
| September 30, 2015 | 10.05M |
| June 30, 2015 | 7.508M |
| March 31, 2015 | 6.494M |
| December 31, 2014 | 5.242M |
| September 30, 2014 | 3.693M |
| June 30, 2014 | 2.837M |
| March 31, 2014 | 2.717M |
| December 31, 2013 | 2.711M |
| September 30, 2013 | 1.475M |
| June 30, 2013 | 1.203M |
| March 31, 2013 | 1.118M |
| December 31, 2012 | 10.59M |
| September 30, 2012 | 0.763M |
| June 30, 2012 | 0.547M |
| March 31, 2012 | 0.386M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.914M
Minimum
Sep 2020
4.196M
Maximum
Dec 2023
2.490M
Average
2.597M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Merck & Co Inc | 5.862B |
| Pro-Dex Inc | 0.843M |
| BioCardia Inc | 0.80M |
| NovaBay Pharmaceuticals Inc | 0.009M |
| Palatin Technologies Inc | 4.672M |